Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis

NCT00035334 is registered in ClinicalTrials.gov with Bellus Health Inc. - a GSK company as lead sponsor.

NCT NCT00035334
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00035334 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis
Lead sponsor
Bellus Health Inc. - a GSK company
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2001
Completion date
December 31, 2004
Enrollment
150
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

familial mediterranean syndrome, gastrointestinal diseases, kidney diseases, nephrotic syndrome, rheumatoid arthritis, secondary (aa) amyloidosis